Cool-To The Moon - Tiger Brokers Online Investing Community

1
Comment
Favorite

Cool bird
2022-04-29

Cool

Pfizer to Start U.S. Trial of Gene Therapy as FDA Lifts Hold

April 28 (Reuters) - Pfizer Inc said on Thursday it would open the first U.S. trial sites for its ex

Pfizer to Start U.S. Trial of Gene Therapy as FDA Lifts Hold

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

Cool bird
·2022-04-29
Yea
Reply
Like
Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9060432909,"tweetId":"9060432909","gmtCreate":1651187865707,"gmtModify":1676534864821,"author":{"id":3576790897131947,"idStr":"3576790897131947","authorId":3576790897131947,"authorIdStr":"3576790897131947","name":"Cool bird","avatar":"https://static.tigerbbs.com/2a18793145d8e701bbc80926ad081518","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[],"fanSize":28,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Cool</p></body></html>","htmlText":"<html><head></head><body><p>Cool</p></body></html>","text":"Cool","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9060432909","repostId":2230944386,"repostType":4,"repost":{"id":"2230944386","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1651158214,"share":"https://www.laohu8.com/m/news/2230944386?lang=&edition=full","pubTime":"2022-04-28 23:03","market":"us","language":"en","title":"Pfizer to Start U.S. Trial of Gene Therapy as FDA Lifts Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2230944386","media":"Reuters","summary":"April 28 (Reuters) - Pfizer Inc said on Thursday it would open the first U.S. trial sites for its ex","content":"<html><head></head><body><p>April 28 (Reuters) - Pfizer Inc said on Thursday it would open the first U.S. trial sites for its experimental gene therapy for a muscle-wasting disorder, after the Food and Drug Administration lifted its hold on a late-stage study.</p><p>The FDA had put Pfizer&#39;s trial request on hold after the death of a patient in another early-stage study of the therapy for Duchenne muscular dystrophy (DMD), which was also paused.</p><p>Pfizer said the regulatory clearance came after data reviews and tweaks to the trial to include a seven-day hospitalization period to closely monitor patients receiving the gene therapy.</p><p>The late-stage study had been underway in 11 countries before it was halted. So far, Pfizer has received clearance from countries including the United Kingdom, Canada and Taiwan to restart the late-stage study, the drugmaker said.</p><p>DMD is caused by changes in a gene, which result in the absence of protein called dystrophin involved in keeping muscle cells intact. It mostly affects boys.</p><p>Pfizer&#39;s therapy is designed to deliver a shortened version of the human dystrophin gene.</p><p>The drugmaker expects nearly all sites for the global late-stage study to open by the end of June.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer to Start U.S. Trial of Gene Therapy as FDA Lifts Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer to Start U.S. Trial of Gene Therapy as FDA Lifts Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-04-28 23:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>April 28 (Reuters) - Pfizer Inc said on Thursday it would open the first U.S. trial sites for its experimental gene therapy for a muscle-wasting disorder, after the Food and Drug Administration lifted its hold on a late-stage study.</p><p>The FDA had put Pfizer&#39;s trial request on hold after the death of a patient in another early-stage study of the therapy for Duchenne muscular dystrophy (DMD), which was also paused.</p><p>Pfizer said the regulatory clearance came after data reviews and tweaks to the trial to include a seven-day hospitalization period to closely monitor patients receiving the gene therapy.</p><p>The late-stage study had been underway in 11 countries before it was halted. So far, Pfizer has received clearance from countries including the United Kingdom, Canada and Taiwan to restart the late-stage study, the drugmaker said.</p><p>DMD is caused by changes in a gene, which result in the absence of protein called dystrophin involved in keeping muscle cells intact. It mostly affects boys.</p><p>Pfizer&#39;s therapy is designed to deliver a shortened version of the human dystrophin gene.</p><p>The drugmaker expects nearly all sites for the global late-stage study to open by the end of June.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4007":"制药","BK4534":"瑞士信贷持仓","BK4581":"高盛持仓","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","PFE":"辉瑞"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2230944386","content_text":"April 28 (Reuters) - Pfizer Inc said on Thursday it would open the first U.S. trial sites for its experimental gene therapy for a muscle-wasting disorder, after the Food and Drug Administration lifted its hold on a late-stage study.The FDA had put Pfizer's trial request on hold after the death of a patient in another early-stage study of the therapy for Duchenne muscular dystrophy (DMD), which was also paused.Pfizer said the regulatory clearance came after data reviews and tweaks to the trial to include a seven-day hospitalization period to closely monitor patients receiving the gene therapy.The late-stage study had been underway in 11 countries before it was halted. So far, Pfizer has received clearance from countries including the United Kingdom, Canada and Taiwan to restart the late-stage study, the drugmaker said.DMD is caused by changes in a gene, which result in the absence of protein called dystrophin involved in keeping muscle cells intact. It mostly affects boys.Pfizer's therapy is designed to deliver a shortened version of the human dystrophin gene.The drugmaker expects nearly all sites for the global late-stage study to open by the end of June.","news_type":1},"isVote":1,"tweetType":1,"viewCount":605,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":101488709,"commentId":"101488709","gmtCreate":1651187874124,"gmtModify":1663248077546,"authorId":3576790897131947,"author":{"id":3576790897131947,"idStr":"3576790897131947","authorId":3576790897131947,"name":"Cool bird","avatar":"https://static.tigerbbs.com/2a18793145d8e701bbc80926ad081518","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9060432909,"objectIdStr":"9060432909","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Yea","text":"Yea","html":"Yea","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}